Carrying Out Research About HIV Whole Genome using a Kit Now Available in the USA

• Access to a comprehensive Next Generation Sequencing (NGS) kit for HIV Whole Genome genotyping.
• Ability to screen genomic variations in all HIV-1 genome genes targeted by current and under development HIV-1 inhibitors.

Newburyport (MA, USA) – AdvancedDx Biological Laboratories USA Inc., the US affiliate of ABL Diagnostics (FR001400AHX6 – ABLD), a Euronext-listed French company, is pleased to announce the availability in the USA, of an assay enabling HIV whole genome genotyping by sequencing.

DeepChek® Assay Whole Genome HIV-1 Genotyping has been developed for use with the leading next generation sequencing (NGS) platforms and includes optimized multiplex PCR master mixes with primers to amplify RNA and proviral DNA inputs with manual or automated library preparations.

The comprehensive assay is offering a global screening of mutations on all HIV-1 genomic targets related to HIV-1 inhibitors (reverse transcriptase inhibitors (NRTIs, NNRTIs, NRTTIs), protease inhibitors, integrase and integrase strand transfer inhibitors, capsid inhibitors, attachment and post-attachment inhibitors, and fusion inhibitors) including the new drugs like lenacapavir and cabenuva.

This comprehensive kit is intended for use in discovering and developing medical knowledge related to HIV-1 mutations prevalence and emergence and their possible impact of drug resistance. By analyzing the genetic sequences of HIV-1, one can monitor and control the evolution of the HIV-1 virus, build databases linking mutation patterns and treatment response to develop and update HIV drug resistance interpretation algorithms to optimize antiretroviral therapy strategies, and identify earlier drug resistant viruses to prevent HIV drug resistance transmission. This assay is of interest for either national or international research and public health initiatives.

The company offers an array of Research Use Only kits for use on NGS platforms and for some on Sanger sequencing platforms. This offer includes general laboratory product (GLP) reagents that enable diverse sequencing methods for a variety of sample types and throughput needs. DeepChek® library preparation reagents and universal adapters are for next generation sequencing.

The sequencing outputs can be analyzed with specific downstream sequencing analysis software (e.g. DeepChek® Software) to reduce laboratory staff burden and to alleviate the need for specialized bioinformatics expertise or on the contrary with using generic bioinformatics software and tools for more advanced research teams.

Dimitri Gonzalez, Head of Sales & Marketing explained that “there is a trend for microbiology laboratories to further implement NGS-based technologies in plus of capillary electrophoresis (Sanger) sequencing to perform genotyping analyses on traditional genes but also on additional targets or even the whole genome. Our portfolio should fulfill laboratories in the USA to work on new research projects, such as epidemiological studies related to mutations linked to HIV-1 capsid or entry inhibitors.”

***

ABOUT ADVANCEDDX BIOLOGICAL LABORATORIES USA INC & ABL DIAGNOSTICS

ADVANCEDDX BIOLOGICAL LABORATORIES USA INC is an affiliate of ABL DIAGNOSTICS S.A. (ABLD), a company offering innovative and proprietary molecular biology assays and end-to-end solutions intended to be used by trained laboratory teams in Polymerase Chain Reaction (PCR) and sequencing workflows.

Please consult ABL team for further information about registration status of the ABL products in your territory.

ABL Diagnostics commercializes its entire line of products on a worldwide basis through its own sales team and through a network of exclusive distributors active on all continents. ABL Diagnostics clients are academic clinical pathology labs, private reference labs and researchers willing to implement an innovative and robust microbiology content in constant expansion.

ABL Diagnostics, based in Woippy, is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6).

AdvancedDx Biological Laboratories USA is based in Newburyport (Massachusetts) with warehouse facilities in Fairfield (New Jersey).

For further information, please visit www.abldx.com

CONTACTS

ABL Diagnostics / AdvancedDx Biological Laboratories USA

Dr. Chalom Sayada
CEO
Tel.: +33 7 83 64 68 50
info@abldiagnostics.com

FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning ABL Diagnostics and its business. Such forward-looking statements are based on assumptions that ABL Diagnostics considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the universal registration document filed with the AMF on July 12, 2022 under number 22-296, available on the web site of ABL Diagnostics (www.abldiagnostics.com) and to the development of economic conditions, financial markets and the markets in which ABL Diagnostics operates. The forward-looking statements contained in this press release are also subject to risks not yet known to ABL Diagnostics or not currently considered material by ABL Diagnostics. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of ABL Diagnostics to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for ABL Diagnostics shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.